Boston Scientific Corp. reports $5.2 billion revenue for quarter ended March 31, 2026, up 11.6%
Boston Scientific Corp. reported revenue of $5.2 billion for the quarter ended March 31, 2026, an increase of 11.6% from the same quarter a year earlier ($4.66 billion).
For the same period it posted net income of $1.34 billion, up 99.3%, or $0.90 per diluted share (0.45 a year earlier).
That is a net margin of 25.7%.
On Sanad's AAOIFI Standard 21 screen, Boston Scientific Corp. is currently compliant: interest-bearing debt is 19.2% of market capitalisation (limit 30%), and impure income is 0.5% of revenue (limit 5%).
Is Boston Scientific Corp. halal?
See the full AAOIFI screening of Boston Scientific Corp.
See the full AAOIFI screening of Boston Scientific Corp.
Source: 10-Q filed with the U.S. Securities and Exchange Commission on May 1, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.